Clinical Trial Update: A Study of Oral Ibogaine in Opioid Withdrawal [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 1/2 study evaluating oral ibogaine for opioid withdrawal.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Withdrawal Syndrome

Drugs mentioned

• Ibogaine (ibogaine)

Snippet

Sponsor: atai Therapeutics, Inc. | Conditions: Opiate Withdrawal Syndrome | Phase 1, Phase 2 | Status: COMPLETED